Browsing: approval
Pembrolizumab, an immune control point inhibitor, has been approved by the US Food and Drug Administration (FDA) for the treatment…
Johnson & Johnson announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib)…